A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

Conclusion Despite some evidence of efficacy in this setting, the primary end point for the study was not met. In the era of targeted agents that are well tolerated, the combination of fludarabine and alemtuzumab should be used rarely for a select group of fit patients who are refractory to standard therapies. Micro-Abstract We evaluated alemtuzumab in combination with fludarabine for patients with relapsed chronic lymphocytic leukemia. Sixty patients were enrolled onto this phase 2 study; the complete response rate was 8.3%, with an overall response rate of 28.3%. Although many patients developed cytomegalovirus reactivation, these episodes were manageable. This regimen should be considered only for fit patients refractory to available therapies.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research